The role of methadone in cancer pain treatment - Polish experience

Progress in Palliative Care

Volumn 13, Issue 5, 2005, Pages 269-276

  Leppert, Wojciech ^a   Łuczak, Jacek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cancer pain; Methadone; Opioid analgesics; Opioid rotation; Pain treatment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPIVACAINE; DIPYRONE; FENTANYL; KETAMINE; KETOPROFEN; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; TRAMADOL;

ADULT; AGED; ANALGESIA; ARTICLE; BONE PAIN; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; NAUSEA; NEUROPATHIC PAIN; POLAND; RESPIRATION DEPRESSION; SWEATING; VOMITING;

EID: 28944442994     PISSN: 09699260     EISSN: None     Source Type: Journal    
DOI: 10.1179/096992605X75868     Document Type: Article

References (40)

1. Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay H et al. for the Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. BMJ 2001;84:587-93.
2. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H et al. for the Expert Working Group of the European Association of Palliative Care Network.: Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54.
3. Mercadante S. Opioid rotation for cancer pain. Rationale and clinical aspects. Cancer 1999;86:1856-66.
4. Mercadante S. Predictive factors and opioid responsiveness in cancer pain. Eur J Cancer 1998;34:627-31.
5. De Stoutz ND, Bruera E, Suazer-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-84.
6. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78:852-7.
7. Gannon G. The use of methadone in the care of dying. Eur J Palliat Care 1997;4:152-8.
8. Lussier D, Portenoy RK. Adjuvant analgesics in pain management. Doyle D, Hanks G, Cherny N, Calman K. (eds) Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press, 2004; 349-78.
9. Enting RH, Oldenmenger WH, van der Rijt CCD, Wilms EB, Elfrink EJ, Elswijk I et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer 2002;94:3049-56.
10. Burton AW, Rajagopal A, Shah HN, Mendoza T, Cleeland C, Hassenbusch SJ et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med 2004;5:239-47.
11. Kotlinska Lemieszek A, Luczak J. Subanesthetic ketamine: an essential adjuvant for intractable cancer pain. J Pain Symptom Manage 2004;28:100-2.
12. Bolan EA, Tallarida RJ, Pasternak GW. Synergy between μ opioid ligands: Evidence for Functional Interactions among μ opioid receptor subtypes. J Pharmacol Exp Ther 2002;303:557-62.
13. Mercadante S, Villari P, Ferrera P, Casuccio A. Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 2004;12:762-6.
14. Fishman SM, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: novel clinical applications with related concerns. Pain Med 2002;3:339-48.
15. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995;187:165-8.
16. Codd EE, Schank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274:1263-70.
17. Mancini IL, Hanson J, Neumann CM, Bruera E. Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study, J Palliat Med 2000;3:49-56.
18. Daeninck PJ, Bruera E. Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of four cases. J Pain Symptom Manage 1999;18:303-9.
19. Twycross R, Back I. Nausea and vomiting in advanced cancer. Eur J Palliat Care 1998;5:39-45.
20. Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am 2002;16:543-55.
21. Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9:73-83.
22. Ripamonti C, Bianchi M, Bruera E. Methadone: an orphan drug?, J Palliat Med 2004;7:73-4.
23. Ripamonti C, Zecca E, Brunelli C, Rizzio E, Salta L, Lodi F et al. Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 1995;6:841-3.
24. Hagen NA, Wasylenko E. Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 1999;18:369-75.
25. Mercadante S, Casuccio A, Agnello A, Barresi L. Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage 1999;18:188-92.
26. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996;14:2836-42.
27. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001;19:2898-904.
28. Mercadante S, Cassuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999;17:3307-12.
29. Manfredi PL, Foley KM, Payne R, Houde R, Inturissi CE. Parenteral methadone: an essential medication for the treatment of pain. J Pain Symptom Manage 2003;26:687-8.
30. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998;16:3216-21.
31. Nauck F, Ostgathe C, Dickerson ED. A German model for methadone conversion. Am J Hosp Palliat Care 2001;18:200-2.
32. Leppert W. The role of methadone in opioid rotation in severe cancer pain. Abstracts of the 17th MASCC International Symposium, Geneva, Switzerland, June 30-July 2, 2005. Support Care Cancer 2005;13:458-9.
33. Soares LGL. Methadone for cancer pain: what have we learned from clinical studies? Am J Hosp Palliat Care 2005;22:223-7.
34. Gazelle G, Fine PG. Methadone for pain. J Palliat Med 2004;7:303-4.
35. Morley J, Mankin M. The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev 1998;5:51-8.
36. Manfredi PL, Houde RW. Prescribing methadone, a unique analgesic. J Support Oncol 2003;1:216-20.
37. Fisher K, Stiles C, Hagen NA. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 2004;28:619-25.
38. Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: respiratory depression by drug interaction. J Pain Symptom Manage 2002;23:148-53.
39. Bruera E, Palmer JN, Bosnjak S, Rico MA, Moyano J et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004;22:185-92.
40. Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol 1998;16:3656-61.